Nalmefene Smoking Cessation Study

S

Somaxon Pharmaceuticals

Status and phase

Completed
Phase 2

Conditions

Smoking Cessation

Treatments

Other: Placebo
Drug: nalmefene

Study type

Interventional

Funder types

Industry

Identifiers

NCT00202696
SP-N0408

Details and patient eligibility

About

To determine if nalmefene is safe and effective in smoking cessation.

Full description

Single centered, randomized, placebo-controlled,double-blind, outpatient pilot study to evaluate the efficacy, safety and tolerability of 2 doses of nalmefene on smoking cessation.

Enrollment

76 patients

Sex

All

Ages

25 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Smokers in good general health self reporting more than 15 cigarettes per day

Exclusion criteria

-

Trial design

76 participants in 3 patient groups

1
Experimental group
Description:
Nalmefene 40 mg
Treatment:
Drug: nalmefene
2
Experimental group
Description:
Nalmefene 80 mg
Treatment:
Drug: nalmefene
3
Other group
Description:
Placebo
Treatment:
Other: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems